¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Lymphocyte Antigen 96"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antigen recognition
    Ç׿øÀνÄ
  • antigen-antibody complex
    Ç׿øÇ×üº¹ÇÕü
  • antigen-antibody interaction
    Ç׿øÇ×ü»óÈ£ÀÛ¿ë
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • avidin-antigen conjugate
    ¾ÆºñµòÇ׿øÁ¢ÇÕü
  • capsid antigen
    ĸ½ÃµåÇ׿ø
  • capsular antigen
    ÇǸ·Ç׿ø
  • common antigen
    °øÅëÇ׿ø
  • complete antigen
    ¿ÏÀüÇ׿ø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antigen analysis
    Ç׿øºÐ¼®
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
  • antigen binding capacity
    Ç׿ø°áÇÕ´É
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen diffusion constant
    Ç׿øÈ®»ê»ó¼ö
  • antigen excess zone
    Ç׿ø°úÀ×±¸¿ª
  • antigen-antibody complex
    Ç׿øÇ×üº¹ÇÕü
  • antigen-antibody interaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-presenting cell
    Ç׿øÀü´Þ¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • DP antigen
    DPÇ׿ø
  • DQ antigen
    DQÇ׿ø
  • DR antigen
    DRÇ׿ø
  • Diego antigen
    µð¿¡°íÇ׿ø
  • EB nuclear antigen(EBNA0
    EB ¹ÙÀÌ·¯½º ÇÙÇ׿ø
  • EB nuclear antigen (EBNA)
    EB¹ÙÀÌ·¯½º ÇÙÇ׿ø
  • EBV capsid antigen
    EB¹ÙÀÌ·¯½º ĸ½Ãµå Ç׿ø
  • EBV capsid antigen (VCA)
    EB¹ÙÀÌ·¯½º ĸ½ÃµåÇ׿ø
  • EBV membrane antigen
    EB¹ÙÀÌ·¯½º ¸·Ç׿ø
  • EBV membrane antigen (MA)
    EB¹ÙÀÌ·¯½º ¸·Ç׿ø
  • Forssman antigen
    Æ÷½º¸¸Ç׿ø
  • Fy antigen/antibody
    Fy Ç׿ø/Ç×ü
  • Gag => group specifiic antigen/core
    ±×·ì<±º>ƯÀ̼º Ç׿ø/ÄÚ¾î
  • Gag antigen in HIV infection
    HIV °¨¿°ÀÇ gag Ç׿ø
  • Gag antigen:
    gag Ç׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • lymphocyte transformation
    ¸²ÇÁ±¸Àüȯ(¡­Ï¹ ï®üµ).
  • lymphocyte, resident
    »óÁÖ¸²ÇÁ±¸
  • lymphocyte-activating determinant
    ¸²ÇÁ±¸È°¼º °áÁ¤±â
  • lymphocyte-derived chemotactic factor
    ¸²ÇÁ±¸À¯·¡ È­ÇÐÁÖ¼ºÀÎÀÚ
  • medium sized lymphocyte
    Á߸²ÇÁ±¸(ñ顭Ϲ).
  • medium sized lymphocyte
    Á߸²ÇÁ±¸(Ì¡?Ë´).
  • medium-sized lymphocyte
    Áß°£¸²ÇÁ±¸
  • mixed lymphocyte culture
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç(̴̰?Ë´ËÑËâ).
  • mixed lymphocyte culture
    ¸²ÇÁ±¸È¥ÇÕ¹è¾ç(¡­ûèùêÏ¹ÛÆå×).
  • mixed lymphocyte culture(MLC)
  • mixed lymphocyte reaction
    ¸²ÇÁ±¸ È¥ÇÕ¹è¾ç¹ÝÀÀ
  • mixed lymphocyte response(MLR)
  • monocyte lymphocyte ratio
    ´Ü±¸¸²ÇÁ±¸ºñ(ӤϹ¡­Ï¹Ýï).
  • monocyte lymphocyte ratio
    ´Ü±¸¸²ÇÁ±¸ºñ(ËÀË´?Ë´ËÓ).
  • primed lymphocyte
    ÃÊȸ°¨ÀÛ ¸²ÇÁ±¸
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Ia antigen
    Ia Ç׿ø(ù÷ê«)
  • incomplete antigen
    ºÒ¿ÏÀü Ç׿ø(ÝÕèÇîïù÷ê«)
  • K antigen
    K Ç׿ø
  • LS antigen
    LS Ç׿ø(ù÷ê«)
  • M antigen
    M Ç׿ø(ù÷ê«)
  • MHC antigen
    MHCÇ׿ø(ù÷ê«)
  • NP antigen
    NPÇ׿ø(ù÷ê«)
  • O antigen
    O Ç׿ø(ù÷ê«)
  • P antigen
    P
  • particulate antigen
    ÀÔÀÚ Ç׿ø(Ø£í­ù÷ê«)
  • penton antigen
    ÆæÅæ Ç׿ø(ù÷ê«)
  • protective antigen
    º¸È£ Ç׿ø(ÜÁûÞù÷ê«)
  • R antigen
    R Ç׿ø(ù÷ê«)
  • S antigen
    S Ç׿ø(ù÷ê«)
  • SH-antigen
    SH-Ç׿ø(ù÷ê«)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ABL abetalipoproteinemia; acceptable blood loss; African Burkitt lymphoma; Albright-Butler-Lightwood [sy...
CLA cerebellar ataxia; Certified Laboratory Assistant; cervicolinguoaxial; contralateral local anesthesi...
HBLA human B-cell lymphocyte antigen
HLA-SD human lymphocyte antigen-serologically defined
HTLA high-titer, low acidity; human T-lymphocyte antigen
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
SLA Swine Lymphocyte Antigen
LFA-1 anti-lymphocyte function associated antigen-1
BoLA bovine lymphocyte antigen
T-antigen Thomsen Friedenreich antigen
T-antigen Tumor antigen
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antigen shift
    Ç׿ø ´ëº¯ÀÌ
  • antigen unit
    Ç׿ø ´ÜÀ§
  • antigen-antibody reaction
    Ç׿ø-Ç×ü ¹ÝÀÀ
  • carcinoembryonic antigen assay
    ¾Ï ¹è¾Æ¼º Ç׿ø ÃøÁ¤, ¾Ï¼º ¹è¾Æ¼º Ç׿ø ÃøÁ¤
  • class I human leukocyte antigen
    Á¦ 1±Þ ÀÎü ¹éÇ÷±¸ Ç׿ø
  • class II human leukocyte antigen
    Á¦ 2±Þ ÀÎü ¹éÇ÷±¸ Ç׿ø
  • dander antigen
    Àμ³ Ç׿ø
    ÇǺÎÀÇ Ç¥¸éÀ¸·ÎºÎÅÍ ²÷ÀÓ¾øÀÌ »êÆ÷µÇ°í ÀÖ´Â ¹°ÁúÀÇ È¥ÇÕ¹°. ¹Ú¸®µÈ »óÇÇ ¼¼¹Î, ÅÐÀÇ ´ÜÆí, ÇǺÎÀÇ Áö¹æ µîÀÌ Æ÷ÇԵǴµ¥ ƯÈ÷ Àμ³ÀÌ Áß¿äÇÏ´Ù. ¾ÆÅäÇǰ¡ ÀÖ´Â »ç¶÷¿¡¼­´Â Áï½ÃÇü °ú¹ÎÁõÀÇ ¿øÀÎÀÌ µÇ´Â ¼ö°¡ ÀÖ´Ù.
  • determinant antigen
    Ç׿ø °áÁ¤±º, °áÁ¤ Ç׿ø
    ¸é¿ªÇÐÀû ƯÀ̼ºÀ» °áÁ¤Çϴ ƯÁ¤ÀÇ È­ÇÐÀûÀÎ ºÐÀÚ±º.
  • diego antigen
    µð¿¡°í Ç׿ø
  • differentiation antigen
    ºÐÈ­ Ç׿ø
    ¼¼Æ÷°¡ ºÐÈ­ÇØ °¡´Âµ¥ À־ Ç¥ÇöµÇ´Â ¼¼Æ÷¸· »óÀÇ Ç׿ø. T ¼¼Æ÷¿¡¼­´Â B ¼¼Æ÷·ÎºÎÅÍ ±¸º°ÇÏ´Â ºÐÈ­ Ç׿øÀº mouse »çÀÌ¿¡¼­ ¼¼Æ÷¸¦ Åõ¿©ÇÏ¿© ¸¸µé¾îÁø µ¿Á¾ Ç×Ç÷û¿¡ ÀÇÇÏ¿© °ËÃâµÇ´Â Ç׿ø
  • DR antigen
    DR Ç׿ø
    HLA-D ¿µ¿ª À¯ÀüÀÚÀÇ Áö¹è¸¦ ¹Þ´Â Ç׿øÀ̸ç, ÁÖ·Î B ¼¼Æ÷ ¹× macro
  • endogenous antigen
    ³»ºÎ Ç׿ø
    µ¿¹°ÀÇ Ã¼³»¿¡ Á¸ÀçÇÏ´Â °Íµé·Î¼­ µ¿¹°ÀÇ Á¶Á÷, ¼¼Æ÷ÀÇ ÀϺΠ±¸¼º ¼ººÐ µîÀÌ ¿©±â¿¡ ¼ÓÇÑ´Ù.
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • fetal antigen
    ÅÂ¾Æ Ç׿ø
    Á¾¾ç °ü·Ã Ç׿øÀÇ ÀÏÁ¾, Å»ý±â Á¶Á÷¿¡¼­´Â ÀÎÁ¤µÇÁö¸¸, Á¤»óÀûÀÎ ºÐÈ­¸¦ ¹âÀº Á¶Á÷¿¡¼­´Â ÀÎÁ¤µÇÁö ¾Ê°Å³ª ±ØÈ÷ ¹Ì·® Á¸ÀçÇϰųª ÇÑ´Ù.
  • H antigen
    H Ç׿ø
    1. ¿îµ¿¼º ¼¼±ÕÀÇ Æí¸ð Ç׿ø 2. H-¹°Áú.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
T lymphocyte <haematology, immunology> A class of lymphocytes, so called because they are derived from the thymus and have been through thymic processing. Involved primarily in controlling cell-mediated immune reactions and in the control of B-cell development, aiding B lymphocytes in making antibodies, and helping in the recognition and rejection of foreign tissues. T lymphocytes are also important in the bodys defense against cancer.
They bear T-cell antigen receptors (CD3) and lack Fc or C3b receptors. Major T-cell subsets are CD4 (mainly helper cells) and CD8 (mostly cytotoxic or suppressor T-cells). Uncontrolled proliferation of this type of cell gives rise to T-cell leukaemia/lymphoma.
(13 Nov 1997)
t-lymphocyte A white blood cell made in the thymus gland, a lymphoid structure in the upper chest. T lymphocytes are also called T-cells. (the t in T-cell stands for thymus). These cells coordinate the immune system by secreting lymphokine hormones. There are 3 fundamentally different types of t lymphocytes : helper, killer, and suppressor.
(12 Dec 1998)
t-lymphocyte subsets A classification of T-lymphocytes, especially into helper/inducer, suppressor/effector, and cytotoxic subsets, based on structurally or functionally different populations of cells.
(12 Dec 1998)
transformed lymphocyte See: lymphocyte transformation.
(05 Mar 2000)
epitopes, b-lymphocyte Antigenic determinants recognised and bound by the B-cell receptor. Epitopes recognised by the B-cell receptor are located on the surface of the antigen.
(12 Dec 1998)
epitopes, t-lymphocyte Antigenic determinants recognised and bound by the T-cell receptor. Epitopes recognised by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen.
(12 Dec 1998)
tumour-infiltrating lymphocyte <haematology, oncology> Special cancer-fighting cells of the immune system found in tumours. In a type of experimental therapy, scientists harvest these cells from the tumour, grow them in a laboratory and then return them to the patient with the hope of the cells destroying the tumour.
These cells can be collected from the site of a tumour and exposed to IL-2 in vitro. When these cells are injected back into the tumour bearing host, they will specifically kill the tumour from which they originated.
(05 Mar 2000)
lymphocyte <haematology> White cell of the blood that are derived from stem cells of the lymphoid series.
Two main classes are recognised, T and B lymphocytes, the latter responsible (when activated) for production of antibody, the former subdivided into subsets (helper, suppressor, cytotoxic T-cells) and responsible both for cell-mediated immunity and for stimulating B-cells.
(18 Nov 1997)
lymphocyte activation <haematology> The change in morphology and behaviour of lymphocytes exposed to a mitogen or to an antigen to which they have been primed. The result is the production of lymphoblasts, cells that are actively engaged in protein synthesis and that divide to form effector populations. Should not be confused with transformation of the type associated with oncogenic viruses and activation is therefore perhaps a better term.
(18 Nov 1997)
lymphocyte cooperation T-cell enhancement of the B-cell response to thymic-dependent antigens.
(12 Dec 1998)
lymphocyte count A count of the number of lymphocytes in the blood.
(12 Dec 1998)
lymphocyte depletion Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.
(12 Dec 1998)
lymphocyte-oriented kinase <enzyme> An ste20-like protein kinase; genbank d89728
Registry number: EC 2.7.10.-
Synonym: lok gene product
(26 Jun 1999)
lymphocyte specific protein tyrosine kinase p56(lck) <enzyme> This enzyme is a lymphoid specific src family tyrosine kinase that is critical for T-cell development and activation. Lck is associated with the cytoplasmic domains of CD4, CD8 and the beta-chain of the il-2 receptor, and is thought to be involved in the earliest steps of tcr-mediated T-cell activation.
Registry number: EC 2.7.11.-
(12 Dec 1998)
lymphocyte subsets A classification of lymphocytes based on structurally or functionally different populations of cells.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á